Ga Syfovre denied as duplicate or overlapping therapy by Aetna?

Aetna's specific coverage criteria for ga syfovre are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Denies Syfovre as Duplicate Therapy — and How to Appeal

Syfovre (pegcetacoplan) is an intravitreal injection approved by the FDA for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). A duplicate-therapy denial from Aetna typically occurs when the plan's system detects that a patient is already receiving another anti-complement or intravitreal agent — most commonly Izervay (avacincaptad pegol), which also targets GA — and the plan's policy does not authorize concurrent use of both agents for the same indication.

## Why This Denial Is Appealable

Duplicate-therapy edits are applied algorithmically and do not account for the clinical reason a prescriber has chosen one agent over another, or why a transition in therapy is occurring. If the patient was receiving a prior agent and is transitioning — not continuing both — the denial is factually incorrect and should be reversed on that basis alone. If your retina specialist has a documented clinical rationale for the choice of Syfovre specifically, that individualized judgment is the foundation of a strong appeal.

## Federal Appeal Rights

• ACA §2719 / ERISA §503: You are entitled to a full-and-fair internal review and the specific policy criteria used to make the determination.
• External Review: If the internal appeal is denied, an Independent Review Organization (IRO) must review the case on its clinical merits. The window to request external review is approximately four months from the final internal denial. Expedited review is available when a delay would jeopardize vision or health.

## Appeal Timeline

1. Obtain Aetna's written denial stating the specific duplicate-therapy policy cited. 2. Clarify in writing whether the patient is transitioning from the prior agent (not receiving both). 3. Submit the internal appeal with the prescriber letter and supporting records. 4. Escalate to external review if the internal appeal is upheld.

## Documentation to Gather

• Prescription and claims history: Documentation confirming the prior agent has been discontinued, or a clear explanation of why concurrent use is clinically distinct.
• Diagnosis confirmation: Retinal imaging (e.g., fundus photography, OCR-A, or FAF) confirming the GA diagnosis, lesion characteristics, and progression.
• Prescriber medical-necessity letter: Your retina specialist should explain the specific rationale for selecting Syfovre — including mechanism-of-action considerations and why this agent is appropriate for this patient's presentation — and confirm there is no concurrent duplicate use.
• Clinical severity documentation: Chart notes documenting GA lesion size, location relative to fovea, and rate of progression.

## Criteria-Mapping Strategy

Obtain the current Aetna Clinical Policy Bulletin for intravitreal anti-complement therapy for geographic atrophy. List every criterion and answer each with a specific chart fact. If the policy's duplicate-therapy restriction is based on concurrent dispensing, provide pharmacy records confirming the prior agent was discontinued before Syfovre was initiated. Reference the FDA-approved prescribing information for Syfovre to confirm the approved indication and that this patient's diagnosis aligns with it. The applicable retinal society guidelines (such as those from the American Academy of Ophthalmology) can be cited generically by your prescriber to support appropriate patient selection.